Compare Amgen, Inc. (AMGN) vs Expensify Inc (EXFY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Expensify Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Expensify Inc trades at $1.89 (market cap $182.27M). The key difference: Amgen, Inc. is far larger — about 1076× Expensify Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Expensify Inc pays none. Which is the better fit depends on your goals.
| AMGN | EXFY | |
|---|---|---|
Market Cap | $196.12B | $182.27M |
Sector | Health | Technology |
52-Week High | $388.16 | $2.33 |
52-Week Low | $271.18 | $0.75 |
Enterprise Value | $241.41B | $121.30M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
EXFY trades at $1.89, down 3.08% today, with a bullish technical signal from moving averages and oscillators. The company reported Q1 2026 EPS of $0.04, beating expectations, but maintains negative net income margins. Recent news highlights AI expansion and a $25 million stock buyback program, indicating management confidence despite financial challenges.
Outlook remains mixed with strong analyst buy ratings (44%) but persistent profitability issues. Key opportunities include AI product growth and cash flow stability, while risks involve sustained losses and competitive pressures. The stock presents a speculative opportunity with high volatility potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
